Christos Markellos

MedOnc @UoAofficial @AthensMedicalCenter _ Proud Olympiacos Fan 🔴⚪️

[Christos Markellos @krismarkellos]

@OncBrothers @scserendipity1 @BalazsHalmosMD @lungoncdoc @ipreeshagul @dr_yakupergun @BijoyTelivala @christine_lovly @christinemphmd @PTarantinoMD https://t.co/ntbPdALXx3

[Christos Markellos @krismarkellos]

Daraxonrasib hits the 12-month milestone in OS for the first time in #PDAC , even when given in the 2nd line.
HR 0.4! 🔥
Huge news for our patients! @OncoAlert #OncTwitter

[Oscar Tahuahua @OscarTahuahua]

What REALLY makes a good oncologist? in @JCO_ASCO

After 10 years and 203 JCO essays, one thing became clear: expertise alone isn’t enough.

Patient-centered care.
Clear, authentic communication.
Emotional intelligence.

And the harder work

Showing up again and again.
Openness to uncertainty.
Carrying the burden of cancer care.

Continuous growth.

Clinical competence is expected
Human connection makes the difference.

Science treats disease.
Presence treats fear.
https://t.co/g9hGjSLpGu @OncoAlert

[Christos Markellos @krismarkellos]

@PTarantinoMD Should we proceed with subdividing the 'up to 3:00 PM' group into smaller time increments?

[Christos Markellos @krismarkellos]

@Dr_R_Kurzrock On what data is the reduced dose based?

[Christos Markellos @krismarkellos]

@g_mountzios Off label Osi+Chemo

[Drew Moghanaki @DrewMoghanaki]

Below is a list of "Never Words" to avoid around patients. 🧐 https://t.co/f2Iz9n8AC6

[Christos Markellos @krismarkellos]

@EAntonarakis @ThePCCTC @neerajaiims @ArulChinnaiyan @ZacheryReicher1 @LeonidasPlatan1 Do you believe that this also applies to those patients who have received ADT+ NHT in mCSPC?

[MikaLion @MichalisLiontos]

Science must protect thinking time in a world of instant communication https://t.co/mIAU9CukXr

[Toni Choueiri, MD @DrChoueiri]

Standing ovation for a very poignant and just beautiful opening session by @ASCOPres Dr. Lynn Schuchter “The art & science of cancer care: from comfort to cure”—it is all about our patients.

@ASCO #ASCO24

[Christos Markellos @krismarkellos]

@tnewsomdavis Consistent with ORIENT-31 results for the IO/ anti VEGF combo

[Elena Castro @Ecastromarcos]

Genes that should be included in germline testing panels by tumor type (including prostate cancer): ASCO guideline just published.

https://t.co/uhbKLB8rm6

[Vinay Prasad MD MPH @VPrasadMDMPH]

Our new paper shows just how volatile PFS is based on censoring

You haven't seen anything like this!👇

[Christos Markellos @krismarkellos]

@IbrahimSahinMD1 Is in colon cancer HER2 amplification(NGS) always concordant with HER2 overexpression (IHC)? Should we test both? Different inclusion criteria used across trials, some including amplification, others not.

[Christos Markellos @krismarkellos]

@Markuseckstein3 Fusions frequency 15% in Thor trial. IMO RNA sequencing is mandatory.

[Christos Markellos @krismarkellos]

@MichalisLiontos @DrChoueiri @motzermd @TiansterZhang @PGrivasMDPhD @brian_rini @mtsiatas @OncoAlert It’s cps vs tps. Also in CM-914 90% PD-L1 negative OR non evaluable. No data on how many of them were really negative.

[Giannis Mountzios @g_mountzios]

After 2 yrs of work,just out in @NatRevClinOncol a fully updated review on #IO in resectable #NSCLC. Proud to have worked with a stellar team,special 🙏to my genius 1st coauthor @JordiRemon, senior author @peters_solange for her wisdom and EiC @DianaNrco for her constant support

[Christos Markellos @krismarkellos]

@PTarantinoMD Yes but in what percent of cells? Should we use 10% or 30% as in @Dr_R_Kurzrock study?

[Christos Markellos @krismarkellos]

@ArndtVogel @WCGIC @myESMO @OncoAlert Is it predictive or just prognostic?